I think it's essential to do a couple of things. One is to ensure that any such conditions placed on a licence to market a drug and to keep doing post-market studies be made publicly known so that others can both hold the company to account and the regulator to account to be following up on those particular conditions.
Then, if those studies are done but not necessarily published, that information should be communicated to Health Canada. If Health Canada has the ability to disclose that information because it's making ongoing decisions perhaps to transition a conditional licence to a licence without any more conditions because this post-market study has been fulfilled, then it would have to disclose that at that point. So the specific recommendation I made about making sure that Health Canada's decisions are transparent would hopefully enable the regulator to put up any post-market studies that are done. Even if the company doesn't take it upon itself to publish those on its own, the regulator could do that on its behalf.